

AD _____

Award Number: W81XWH-06-1-0738

TITLE: Role of STAT5b in Breast Cancer Progression and Metastasis

PRINCIPAL INVESTIGATOR: Teresa Bernaciak

CONTRACTING ORGANIZATION: University of Virginia
Charlottesville, VA 22904

REPORT DATE: September 2008

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-09-2008		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 1 Sep 2007 - 30 Aug 2008	
4. TITLE AND SUBTITLE Role of STAT5b in Breast Cancer Progression and Metastasis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-06-1-0738	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Teresa Bernaciak E-Mail: tmb5d@virginia.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Virginia Charlottesville, VA 22904				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The signal transducer and activator of transcription (STAT) 5b is involved in tumorigenic signaling in a number of cancers including breast cancer. However, its importance in breast cancer migration has not been investigated. This research aims to determine the role of STAT5b in breast cancer migration. Knockdown of STAT5b inhibited migration of human breast cancer cells to serum by 60-80%. This inhibition could be rescued by re-introduction of wild-type STAT5b as well as a transcriptionally inactive Y699F-STAT5b mutant. This suggests that the transcriptional activity of STAT5b is not required for its pro-migratory function. Knockdown of STAT1 also inhibited migration of MDA-MB-231 cells but knockdown of STAT3 or STAT5a had no effect. This data demonstrates that STAT5b is integral to breast cancer cell migration and that this effect may occur through a novel, non-transcriptional function. Further elucidating the mechanism by which STAT5b promotes migration of breast cancer cells may lead to more effective therapies for preventing and treating metastasis.					
15. SUBJECT TERMS breast cancer, STAT5b, EGFR, migration, invasion, metastasis					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	16	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction	4
Body	5-11
Key Research Accomplishments	12
Reportable Outcomes	13
Conclusion	14
References	15-16
Appendices	n/a

Introduction

Breast cancer is the second most common cancer in American women. Despite improvements in detection and the development of new treatment strategies, the American Cancer Society estimates that over 180,000 new cases of breast cancer will be diagnosed, and 40,000 women will die from breast cancer this year alone. Because many cancers arise from dysregulation of signaling pathways found in normal cells, one of the difficulties in treating cancers is identifying cancer-specific therapeutic targets. Many tumorigenic signaling pathways converge on common nuclear transcription factors and therefore, targeting these downstream proteins may be efficacious [1]. One such group of transcription factors is the signal transducer and activator of transcription (STAT) family. STATs are a family of transcription factors activated by cytokines and/or growth factors. Activation of STATs 1, 3, and STAT5a/b occurs in a variety of cancers including breast cancer [2, 3]. In general, STAT1 appears to function as a tumor-suppressor while activation of STAT3 and STAT5a/b promote tumorigenesis [4-8]. Both STAT3 and STAT5b promote motility of prostate cancer cells, but their role in breast cancer cell migration has not been examined [9, 10]. STAT5b is a downstream effector of epidermal growth factor receptor (EGFR) signaling [11-13]. Therefore, we sought to investigate the potential role of STAT5b in the migration of two highly aggressive, EGFR-overexpressing breast cancer cell lines, BT-549 and MDA-MB-231, using siRNA knockdown. We found that STAT5b was required for the migration of both of these cell lines. These results establish an important pro-migratory function of STAT5b in EGFR-overexpressing breast cancer cells, further defining its role in tumorigenesis and supporting its potential as a therapeutic target for the treatment of breast cancer.

Body

Task 1: Determine the role of EGF-induced STAT5b activity in breast cancer metastasis

A. Investigate the effects of EGF-induced STAT5b activation on migration and invasion of breast cancer cells

As reported in the year one annual summary report, the design of our migration studies was modified from that originally proposed. First, our studies utilized fetal bovine serum as a chemoattractant, rather than epidermal growth factor (EGF), to stimulate migration of both BT-549 and MDA-MB-231 breast cancer cells, as this was a more potent migratory stimulus for these cells. Secondly, our studies were designed to answer whether STAT5b is necessary for breast cancer cell migration, rather than if it is sufficient to stimulate migration. Therefore, we used siRNA knockdown of STAT5b in highly migratory breast cancer cells as opposed to transient overexpression of STAT5b in non-migratory normal breast epithelial cells.

STAT5b knockdown inhibits breast cancer cell migration - Knockdown of STAT5b to undetectable levels in BT-549 human breast cancer cells inhibited their migration to serum by approximately 70% (Figure 1A). To ensure that this effect was not unique to one cell line, we tested the effect of STAT5b siRNA on migration of MDA-MB-231 cells, another highly aggressive, migratory breast cancer cell line. In these cells, specific knockdown of STAT5b also inhibited migration to serum, by approximately 50% (Figure 1B).

In the BT-549 cells, we determined the optimal migration conditions for Boyden Chamber transwell assays to be migration to 1% serum over 3 hours. Since these cells require a low dose of serum to migrate, we utilized them to determine whether increasing concentrations of serum could overcome the effect of STAT5b knockdown. As seen in Figure 2A, knockdown of STAT5b significantly inhibited migration of BT-549 cells by 60-80% at all serum concentrations ranging from





Figure 1: Knockdown of STAT5b inhibits breast cancer cell migration

(A) BT-549 breast cancer cells were transfected with no siRNA (con), control siRNA for luciferase (siLuc) or siSTAT5b SMARTpool (siSTAT5b) using Oligofectamine. Seventy-two hours following transfection, cells were plated in serum-free media in Boyden Chambers. Media containing 1% FBS was placed in the lower chambers to serve as a chemoattractant. After three hours the cells were fixed, stained with crystal violet, and the number of migratory cells was counted. Four fields were counted on each of two filters. Results are graphed as the average number of migratory cells per field \pm SE. The average cells per field \pm SE for five independent experiments are as follows: con (47.15 ± 4.62), siLuc (43.50 ± 4.80), siSTAT5b (15.48 ± 1.51). Student's *t* test was used to determine statistical significance between the following: con and siSTAT5b *, $p < 0.0001$; siLuc and siSTAT5b •, $p < 0.0001$. (B) MDA-MB-231 cells were transfected with no siRNA (con), control siRNA for luciferase (siLuc), or siRNA specific to STAT5b (siSTAT5b siGENOME SMARTpool oligonucleotide #3) and migration was measured in the same manner as BT-549 cells except that Boyden Chamber assays were performed using 10% FBS in the lower chambers for six hours. The average cells per field \pm SE for four independent experiments are as follows: con (97.09 ± 16.21), siLuc (99.81 ± 17.02), siSTAT5b (48.47 ± 7.84). Student's *t* test was used to determine statistical significance between the following: con and siSTAT5b *, $p = 0.0017$; siLuc and siSTAT5b •, $p = 0.0015$. (A, B) *Upper panels* - Whole cell lysates from siRNA-transfected BT-549 and MDA-MB-231 breast cancer cells were collected seventy-two hours post-transfection and immunoblotted with antibodies specific for STAT5a or STAT5b and β -actin as a loading control.

0.1% to 10%. Thus, increasing the concentration of serum components does not overcome the effect of STAT5b knockdown on inhibiting migration. However, migration is not completely abrogated upon knockdown of STAT5b in either cell line. The cells retain their capacity to migrate at a similar “basal” level across all serum concentrations tested (Figure 2A). To determine whether this residual migration is chemokinesis, or random movement, we performed a checkerboard assay. In this assay, BT-549 cells were plated in upper wells of Boyden Chambers in the presence of media containing varying concentrations of serum. Serum concentrations were also varied in the lower chambers in order to create positive serum gradients, in which serum concentrations are higher in the lower chambers, or negative serum gradients in which serum concentrations are higher in the upper chambers. BT-549 cells migrate chemotactically to serum, seen by an increase in the average number of migratory cells in the presence of a positive serum gradient (Figure 2B). Chemokinetic movement is migration that occurs in the absence of a serum gradient, quantitated in Figure 2B as the values in bold, located between the two lines. In our experiments, an average of approximately 15-26 cells per field randomly migrate. This number is similar to the migration we observed in BT-549 cells in the presence of STAT5b knockdown (Figures 1A, 2A). Therefore, STAT5b knockdown inhibits chemotactic migration of BT-549 breast cancer cells, while the remaining migration can be attributed to chemokinesis.

The effect of STAT5b knockdown on migration is not due to indirect effects on proliferation or survival - It is well established that STAT5b promotes cell cycle progression and survival of breast cancer cells [14-19].


To determine whether knockdown of STAT5b affected cell cycle, survival, or proliferation under the conditions of our migration experiments, we performed trypan blue assays and flow cytometry on knockdown cells seventy-two hours post-transfection. In both BT-549 and MDA-MB-231 cells, knockdown of STAT5b did not significantly alter the total number of adherent cells or the viability of adherent cells over a six hour time period, which is the maximum length of our Boyden Chamber migration assays (Table 1). We also examined the distribution of cells in each phase of the cell cycle following STAT5b knockdown. In BT-549 breast cancer cells, knockdown of STAT5b



increased the percentage of cells in G1 and decreased the percentage of cells in S phase compared to control siLuc knockdown (Figure 3A). A different effect was seen in MDA-MB-231 breast cancer cells, where knockdown of STAT5b increased the percentage of cells in S phase and decreased the percentage of cells in G2 (Figure 3B). These experiments were done simultaneously with Boyden Chamber migration assays in which knockdown of STAT5b inhibited migration in both cell lines. Therefore, while STAT5b knockdown does influence cell cycle distribution, these effects are minimal and do not correlate with the decrease in migration observed. Thus, we conclude that the inhibition of migration upon knockdown of STAT5b is not a result of secondary effects on adherence, viability, or the cell cycle.

Cell Line	siRNA	Adherent Cells (% \pm SE)	Viable Adherent Cells (% \pm SE)	Non-viable Adherent Cells (% \pm SE)
BT-549	con	68.23 \pm 5.73	75.03 \pm 10.98	24.97 \pm 10.98
	siLuc	59.03 \pm 4.64	75.37 \pm 5.43	24.63 \pm 5.43
	siSTAT5b	58.39 \pm 4.61	72.93 \pm 8.01	27.07 \pm 8.01
MDA-MB-231	con	79.22 \pm 2.66	87.13 \pm 1.70	12.87 \pm 1.70
	siLuc	82.12 \pm 1.79	91.72 \pm 0.91	8.28 \pm 0.91
	siSTAT5b	74.14 \pm 5.34	84.33 \pm 4.30	15.67 \pm 4.30

Table 1: The effect of STAT5b knockdown on migration is not due to loss of viability or adhesion
Results listed are for three independent experiments. Student's *t* test was used to determine statistical significance between con and siSTAT5b and siLuc and siSTAT5b. None of these values were statistically significant.



Inhibition of migration upon STAT5b knockdown can be rescued by re-introduction of STAT5b -
To eliminate the possibility of off-target effects of STAT5b knockdown, we performed knockdown-rescue experiments. MDA-MB-231 cells were simultaneously transfected with STAT5b-specific siRNA and hemagglutinin (HA)-tagged wild-type or transcriptionally inactive Y699F forms of STAT5b. The rescue constructs were rendered immune to knockdown by introducing four silent point mutations in the siRNA targeted sequence. Consistent with previous experiments, knockdown of STAT5b inhibited migration of MDA-MB-231 cells by approximately 58%. Re-introduction of wild-type STAT5b restored migration to approximately 76% of control levels. The difference between rescue and control levels of migration was not statistically significant, confirming that the inhibition of migration upon STAT5b knockdown is due to a direct effect of STAT5b on migratory pathways.

Knockdown-rescue experiments can also be used to establish which regions or functions of a protein are necessary for mediating an observed effect. Therefore, we introduced a Y699F-STAT5b mutant to determine whether transcriptional activity of STAT5b is required for promoting migration. The Y699F-STAT5b mutant cannot be phosphorylated on the conserved tyrosine residue necessary for formation of an active dimer and subsequent transcriptional activity [20]. We have previously shown that knockdown of STAT5b inhibits transcription from the STAT5a/b-specific Spi2.1 luciferase reporter and that STAT5b transcriptional activity can be restored by co-transfection of siRNA-immune wild-type STAT5b, but not the Y699F-STAT5b mutant [21]. In migration assays, re-introduction of Y699F-

STAT5b into MDA-MB-231 cells rescued migration to the same level as rescue with wild-type STAT5b (Figure 4A). Together, these results suggest that the canonical transcriptional activity of STAT5b is not necessary for its pro-migratory function.




Figure 4: Re-introduction of both wild-type and transcriptionally inactive STAT5b rescues the migration defect caused by STAT5b knockdown

(A) MDA-MB-231 breast cancer cells were transfected with no siRNA (con), control siRNA to luciferase (siLuc) or siRNA specific to STAT5b (siSTAT5b) alone or in the presence of HA-tagged wild-type or Y699F-STAT5b constructs engineered to be immune to siRNA knockdown. Seventy-two hours following transfection, Boyden Chamber assays were performed for six hours as described in Figure 1. Results are graphed as average migratory cells per field \pm SE for four independent experiments, and are as follows: con (134.47 ± 12.41), siLuc (142.31 ± 10.76), siSTAT5b (57.16 ± 10.88), siSTAT5b + wt-STAT5b (102.58 ± 10.09), siSTAT5b + Y699F-STAT5b (98.44 ± 10.49). Student's *t* test was used to determine statistical significance between the following: con and siSTAT5b *, $p = 0.0034$; siLuc and siSTAT5b •, $p = 0.0014$; siSTAT5b and siSTAT5b + wt-STAT5b ♦, $p = 0.0222$; siSTAT5b and siSTAT5b + Y699F-STAT5b ♦, $p = 0.0341$. Differences between siLuc and either siSTAT5b + wt-STAT5b or siSTAT5b + Y699F-STAT5b were not statistically significant. (B) Whole cell lysates from transfected MDA-MB-231 cells were collected seventy-two hours post-transfection and immunoblotted with antibodies specific for STAT5a, STAT5b, HA, or β -actin as a loading control.




Figure 5: Knockdown of STAT5b or STAT1, but not STAT5a or STAT3, inhibits breast cancer cell migration

(A) MDA-MB-231 cells were transfected with no siRNA (con), control siRNA for luciferase (siLuc), or siRNA specific to STAT5a/b (siSTAT5a/b), STAT5a (siSTAT5a), STAT5b (siSTAT5b), STAT1 (siSTAT1), or STAT3 (siSTAT3). Seventy-two hours following transfection, Boyden Chamber migration assays were performed for six hours as described in Figure 1. Results are graphed as average cells per field \pm SE for six independent experiments (with the exception of siSTAT5a which is the average of five independent experiments, and siSTAT1 which is the average of four independent experiments). Results are as follows: con (136.58 ± 19.78), siLuc (163.96 ± 22.02), siSTAT5a/b (61.02 ± 7.48), siSTAT5a (127.93 ± 30.69), siSTAT5b (61.79 ± 8.98), siSTAT1 (61.69 ± 25.09), siSTAT3 (113.25 ± 20.49). Student's *t* test was used to determine statistical significance between the following: con and siSTAT5a/b *, $p = 0.0051$; con and siSTAT5b *, $p = 0.0063$; con and siSTAT1 *, $p = 0.0457$; siLuc and siSTAT5a/b •, $p = 0.0013$; siLuc and siSTAT5b •, $p = 0.0016$; siLuc and siSTAT1 •, $p = 0.0167$. Comparisons of con and siSTAT5a, con and siSTAT3, siLuc and siSTAT5a, and siLuc and siSTAT3 were not statistically significant. (B) Whole cell lysates from siRNA-transfected MDA-MB-231 cells were collected seventy-two hours post-transfection and immunoblotted with antibodies specific for STAT5a, STAT5b, STAT1, or STAT3, and β -actin as a loading control.

Knockdown of STAT1, but not STAT5a or STAT3, inhibits breast cancer cell migration - STAT5a and STAT5b are highly homologous and are both activated in breast cancer, and previous work has shown that Prl-induced STAT5a activation suppresses migration of BT-20 and T-47D breast cancer cells [22]. Thus, we investigated the role of STAT5a, and other related STATs, STAT1 and STAT3, on migration in our model system. We chose to use the MDA-MB-231 breast cancer cell line because they are highly migratory and express all four STAT proteins. The siSTAT5b SMARTpool siRNA (Dharmacon) used in the BT-549 cell line, while efficient at knocking down STAT5b, also knocks down STAT5a by approximately 60% in MDA-MB-231 cells (Figure 5B, lane 3). To specifically target STAT5b in the MDA-MB-231 cells, we used one of the individual oligonucleotides from the SMARTpool, which had no effect on STAT5a levels (Figure 5B, lane 5). This single oligonucleotide had been used in previous knockdown experiments in the MDA-MB-231 cell line (Figure 1B). The total SMARTpool was utilized to determine the effect of dual knockdown of STAT5a and STAT5b in our MDA-MB-231 model system. It is of note that the BT-549 cell line does not express STAT5a, and therefore, the siSTAT5b SMARTpool was used in these cells without issue (Figure 1A).

As seen previously, knockdown of STAT5b inhibited migration of MDA-MB-231 cells by greater than 50%. In contrast, knockdown of STAT5a had no effect on migration of these cells (Figure 5A). Furthermore, knockdown of STAT5a in combination with STAT5b did not enhance the inhibition of migration due to knockdown of STAT5b alone. Similar to STAT5a, knockdown of STAT3 did not affect migration of MDA-MB-231 cells. Knockdown of STAT1 significantly inhibits their migration, to levels similar to that seen with STAT5b knockdown (55%). In summary, STAT5b and STAT1 are necessary for migration of EGFR overexpressing breast cancer cells, whereas STAT3 and STAT5a are not.

B. Determine if STAT5b is important for metastasis of breast cancer cells *in vivo*

No *in vivo* animal studies have been performed to date.

Task 2: Elucidate the mechanism by which STAT5b promotes breast cancer progression

A. Determine if STAT5b regulates transcription of tumor-secreted proteins Cyr61 and AM

B. Establish whether STAT5b is necessary for Cyr61- and AM- mediated tumor cell migration and invasion

No additional studies have been performed for Task 2 to date.

Future Studies

Future studies will be aimed at elucidating the mechanism by which STAT5b promotes migration of BT-549 and MDA-MB-231 breast cancer cells. First, wound healing assays will be performed in STAT5b knockdown cells with real-time live cell imaging. Wound closure rates and cell morphology will be compared between control and knockdown cells. In addition, immunofluorescence will be utilized to determine the subcellular localization of STAT5b in cells spread on fibronectin. Co-localization of STAT5b with focal adhesions, actin, and tubulin will be examined. These experiments will provide insight into a possible mechanism(s) by which STAT5b promotes migration of these cells.

In addition, the presence of STAT5b-STAT1 heterodimers in BT-549 and MDA-MB-231 cells will be evaluated. Co-immunoprecipitations of STAT5b and STAT1 will be performed in both cell lines to isolate potential heterodimers. Also, GST pulldown assays using GST-tagged wild-type and Y699F-STAT5b will be performed to compare proteins associated with wild-type and transcriptionally inactive STAT5b. Alternatively, nickel isolations of cells transiently transfected with His-tagged wild-type or Y699F-STAT5b may be employed.

Materials and Methods

Cell culture - BT-549 and MDA-MB-231 human breast cancer cell lines were obtained from the American Type Culture Collection (Manassas, VA). Cells were passaged twice per week and maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). All tissue culture reagents were purchased from Invitrogen (Gaithersburg, MD).

siRNA Transfection - BT-549 and MDA-MB-231 cells were transfected with siGENOME SMARTpool siRNA targeting human STAT5b, STAT1, or STAT3, individual custom oligonucleotides specific for STAT5a or STAT5b (siGENOME STAT5b SMARTpool duplex #3), or luciferase duplex control, all purchased from Dharmacon (Lafayette, CO). Transfections were performed using Oligofectamine (Invitrogen) as per manufacturers' instructions. For knockdown-rescue experiments, cells were transfected simultaneously with siSTAT5b SMARTpool duplex #3 and HA-tagged wild-type or Y699F STAT5b engineered to be immune to knockdown by introduction of four silent point mutations in the siRNA target sequence. These point mutations were introduced using QuikChange site-directed mutagenesis (Stratagene, La Jolla, CA) and constructs were sequenced to verify mutations.

Immunoblotting - Cells were lysed in RIPA buffer (150mM NaCl, 50mM Tris, pH 7.4, 1% deoxycholate, 1% Triton X-100, 5mM EDTA) containing protease inhibitor cocktail (Calbiochem, San Diego, CA) and sodium orthovanadate (Sigma, St. Louis, MO). Protein lysates were separated on 7.5% polyacrylamide gels and transferred to nitrocellulose (Pall Corporation, Pensacola, FL). Membranes were blocked in TBST (150mM NaCl, 0.1% Tween 20, 50mM Tris, pH 8.0) containing 5% nonfat dry milk and incubated with primary antibodies in TBST/5% milk. STAT1, STAT5a and STAT5b specific polyclonal antibodies were developed in our lab as previously described [11, 23]. STAT3 polyclonal antibody and β -actin monoclonal antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). HA monoclonal antibody was obtained from the University of Virginia hybridoma facility. Secondary antibodies were applied in TBST and were HRP-conjugated sheep anti-mouse or donkey anti-rabbit (GE Healthcare, Piscataway, NJ). The enhanced chemiluminescence detection kit (GE Healthcare) was used to detect antibody binding. Acrylamide was from Bio-Rad (Hercules, CA), pre-stained molecular weight standards were from Sigma, and all other reagents were of reagent or molecular biological grade from Sigma.

Trypan Blue Assays - Seventy-two hours following siRNA transfection, 4×10^5 cells were transferred to new plates containing DMEM/ 0.1% bovine-serum albumin (BSA) (Sigma) for 6 hours at 37°C. Media was collected, cells were washed in phosphate-buffered saline (PBS) (Invitrogen), and the media and washes were combined to isolate non-adherent cells. Adherent cells were trypsinized and collected separately. Both fractions were stained with trypan blue (Fisher, Herndon, VA) and the total number of cells and number of trypan blue positive cells were counted via hemacytometer.

Propidium Iodide Staining and Flow Cytometry - Approximately 1×10^6 cells were collected and fixed in 70% ethanol for two hours on ice. Fixed cells were washed in PBS and stained in a solution of 20 $\mu\text{g/ml}$ (MDA-MB-231 cells) or 40 $\mu\text{g/ml}$ (BT-549 cells) propidium iodide (Sigma) in 0.1% Triton X-100 containing 200 $\mu\text{g/ml}$ DNase-free RNase A (Qiagen, Germantown, MD) for one hour at room temperature. Cells were analyzed on a FACSCalibur bench cytometer (Becton Dickinson, San Jose, CA) using ModFit software.

Boyden Chamber Migration Assays - BT-549 and MDA-MB-231 cells were transfected with siRNA as described above. Seventy-two hours post-transfection, 5×10^4 BT-549 cells or 1×10^5 MDA-MB-231 cells were plated in serum-free (DMEM/0.1% BSA) media into the upper chambers of BD BioCoat Matrigel Control Chambers (BD Biosciences, San Jose, CA), and various concentration of FBS were placed in the lower chamber. Plates were incubated at 37°C and migration was allowed to proceed for 3-6 hours. After this time, non-migratory cells in the upper chambers were removed with cotton swabs, and the remaining cells were stained with 0.1% crystal violet (Sigma) in 20% ethanol. Cells were counted using a Zeiss Invertoskop light microscope and graphed as average cells per field.

Key Research Accomplishments

- Construction of wild-type and Y699F-STAT5b plasmids immune to siRNA knockdown and optimization of knockdown-rescue experiments
- STAT5b, STAT5a, STAT1, and STAT3 can be specifically and efficiently knocked down in breast cancer cells which express all four STAT family members
- STAT5b plays an integral role in the migration of breast cancer cells to serum
- Knockdown of STAT5b inhibits chemotactic migration of breast cancer cells
- Knockdown of STAT5b does not alter viability, adherence, or cell cycle distribution of breast cancer cells over a 6 hour time period
- Loss of migration upon STAT5b knockdown is rescued with re-introduction of either wild-type or a transcriptionally inactive Y699F-STAT5b mutant
- Knockdown of STAT1 inhibits migration of breast cancer cells to serum
- Knockdown of STAT5a and STAT3 have no effect on breast cancer cell migration to serum

Reportable Outcomes

- Oral presentation
25th Annual American Cancer Society Seminar of Cancer Researchers in Virginia (November 2007; Richmond, VA):
Role of STAT5b in Breast Cancer Cell Migration
University of Virginia
Departments of Microbiology and Medicine and the Cancer Center
- Poster presentation
2008 DOD Era of Hope Meeting (June 2008; Baltimore, MD)
P36-12: Role of Signal Transducer and Activator of Transcription 5B in Breast Cancer Cell Migration
Teresa M. Bernaciak and Corinne M. Silva
University of Virginia
Departments of Microbiology and Medicine and the Cancer Center
- Journal article submission
Bernaciak TM and Silva CM: **Signal transducer and activator of transcription 5b (STAT5b) is an important signaling component of human breast cancer cell migration.**
(submitted to *Breast Cancer Research*)

Conclusion

Our studies demonstrate an integral role for STAT5b in breast cancer cell migration. While a role for STAT5b in breast cancer cell proliferation and survival has already been established, this work is the first to show a positive regulatory role for STAT5b in breast cancer migration. Therefore, STAT5b may not only function in the initiation of tumorigenesis, through its pro-proliferative and pro-survival signaling, but may also promote tumor progression by stimulating migration. Future studies will elucidate the mechanism by which STAT5b exerts its effect on migration, thereby broadening our understanding of how STAT5b promotes tumorigenesis and possibly metastasis. This will facilitate the long-term goal of defining conditions whereby STAT5b would be an effective therapeutic target for the treatment of breast cancer.

References

1. Darnell JE, Jr.: **Transcription factors as targets for cancer therapy.** *Nat Rev Cancer* 2002, **2**(10):740-749.
2. Bowman T, Garcia R, Turkson J, Jove R: **STATs in oncogenesis.** *Oncogene* 2000, **19**(21):2474-2488.
3. Turkson J, Jove R: **STAT proteins: novel molecular targets for cancer drug discovery.** *Oncogene* 2000, **19**(56):6613-6626.
4. Huang S, Bucana CD, Van Arsdall M, Fidler IJ: **Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells.** *Oncogene* 2002, **21**(16):2504-2512.
5. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W: **Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer.** *Clinical Cancer Research* 2002, **8**:3065-3074.
6. Calo V, Migliavacca M, Bazan V, Macaluso M, Buscemi M, Gebbia N, Russo A: **STAT proteins: from normal control of cellular events to tumorigenesis.** *J Cell Physiol* 2003, **197**(2):157-168.
7. Haura EB, Turkson J, Jove R: **Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer.** *Nat Clin Pract Oncol* 2005, **2**(6):315-324.
8. Tan S, Nevalainen MT: **Signal transducer and activator of transcription 5A/B in prostate and breast cancers.** *Endocr Relat Cancer* 2008, **15**(2):367-390.
9. Azare J, Leslie K, Al-Ahmadie H, Gerald W, Weinreb PH, Violette SM, Bromberg J: **Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6.** *Mol Cell Biol* 2007, **27**(12):4444-4453.
10. Kazansky AV, Spencer DM, Greenberg NM: **Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system.** *Cancer Res* 2003, **63**(24):8757-8762.
11. Kloth MT, Catling AD, Silva CM: **Novel activation of STAT5b in response to epidermal growth factor.** *J Biol Chem* 2002, **277**(10):8693-8701.
12. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM: **STAT5b, a mediator of synergism between c-Src and the Epidermal Growth Factor Receptor.** *J Biol Chem* 2003, **278**(3):1671-1679.
13. Weaver AM, Silva CM: **Modulation of signal transducer and activator of transcription 5b activity in breast cancer cells by mutation of tyrosines within the transactivation domain.** *Mol Endocrinol* 2006, **20**(10):2392-2405.
14. Matsumura I, Kitamura T, Wakao H, Tanaka H, Hashimoto K, Albanese C, Downward J, Pestell RG, Kanakura Y: **Transcriptional regulation of the cyclin D1 promoter by STAT5: its involvement in cytokine-dependent growth of hematopoietic cells.** *EMBO J* 1999, **18**(5):1367-1377.
15. Wen X, Lin HH, Shih HM, Kung HJ, Ann DK: **Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells.** *J Biol Chem* 1999, **274**(53):38204-38210.
16. de Groot RP, Raaijmakers JA, Lammers JW, Koenderman L: **STAT5-dependent Cyclin D1 and Bcl-xL expression in Bcr-Abl-transformed cells.** *Mol Cell Biol Res Commun* 2000, **3**(5):299-305.
17. Silva M, Benito A, Sanz C, Prosper F, Ekhterae D, Nunez G, Fernandez-Luna JL: **Erythropoietin can induce the expression of bcl-x(L) through Stat5 in erythropoietin-dependent progenitor cell lines.** *J Biol Chem* 1999, **274**(32):22165-22169.

18. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL: **Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.** *J Exp Med* 2000, **191**(6):977-984.
19. Nieborowska-Skorska M, Hoser G, Kossev P, Wasik MA, Skorski T: **Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis.** *Blood* 2002, **99**(12):4531-4539.
20. Weaver AM, Silva CM: **Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.** *Breast Cancer Res* 2007, **9**(6):R79.
21. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM: **Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.** *Mol Endocrinol* 2008, **22**(8):1781-1796.
22. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H: **Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells.** *Oncogene* 2005, **24**(5):746-760.
23. Silva CM, Lu H, Weber MJ, Thorner MO: **Differential tyrosine phosphorylation of JAK1, JAK2, and STAT1 by growth hormone and interferon-gamma in IM-9 cells.** *J Biol Chem* 1994, **269**(44):27532-27539.